Sign inJoin waitlistJoin the waitlist

IS

Iris Sheng

Hematology & Oncology · University Hospitals Medical Group Inc

Credentials: · · · ·

History

Hematology and Medical Oncology
Cleveland Clinic Foundation
2018–2021
Internal Medicine
Rhode Island Hospital/Brown University Health
2015–2018
Rutgers University
2011–2015

Research

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
Review · Cancer Management and Research · 2020 · First of 2 authors · 39 citations
A 10-year review of open-globe trauma in elderly patients at an urban hospital
Retina · 2015 · First of 5 authors · 37 citations
Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer
International journal of radiation oncology · 2018 · 27 citations

Ankit Mangla
13 papers
Luke Rothermel
13 papers
Jorge Garcia
12 papers
Richard Hoehn
11 papers
Moshe Ornstein
9 papers
HK
Hanna Kakish
8 papers · 8 as a resident
HS
Hailey Seibert
6 papers · 4 as a resident
Jason Brown
6 papers
Maira Bhatty
6 papers · 4 as a resident
Natalie Chakraborty
6 papers · 6 as a resident
Shilpa Gupta
6 papers
Jarred Boone
5 papers · 5 as a resident

Clinical trials

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037